Shanda Ventures
Shanda has always wanted to change the world. As with our philanthropic focus, we believe that human-oriented deep technology has tremendous potential to do this: gene-editing, robotics, anti-aging and brain-related. New, emerging AI technologies are also impacting the world and are part of our investment focus.
To support future innovation, Shanda has invested in 75 up-and-coming, early-stage VC funds under 43 General Partners.
We monitor their portfolios and invest directly when we see best-in-class companies.
- 11.2 Capital Fund II
- Altimeter Venture Partners Fund VII
- Bee Partners III
- Bee Partners IV
- Berkeley SkyDeck Fund I
- Berkeley SkyDeck Fund II
- Boldstart Ventures IV
- Cantos Ventures III
- Catapult
- DCVC VI
- E14 2017 Fund
- E14 2020 Fund
- E14 Fund 3
- Eniac Ventures V
- FFVC Graphite V
- FFVC Violet VI
- FMZ Ventures Fund I
- Foundation Capital IX
- Foundation Capital X
- Foundation Capital Leadership III
- General Catalyst XII
- Greycroft VII
- Griffin Gaming Partners II
- GSV Ventures Fund III
- Hustle I
- Hustle II
- IDG-GTM
- iFly Venture Fund II
- Illumina Ventures II
- Jazz I
- Jazz II
- Jazz Opportunity Fund
- Jazz III
- Jazz Growth Opportunity Fund II
- Khosla Opportunity Fund
- Khosla Opportunity Fund II
- Khosla Ventures VII
- Khosla Ventures VIII
- Khosla Seed E
- Khosla Seed F
- LDV Partners Fund II
- Leonis Capital
- Liberty City Ventures II
- Lightspeed Opportunity II
- Lightspeed Opportunity II_SPV
- MGB Ventures III
- Nava Ventures I
- Neotribe Ventures II
- Obvious Ventures III
- Obvious Growth II
- Obvious Fund IV
- Prime Movers Lab II
- Prime Movers Lab III
- Prime Movers Growth I
- Redtree Fund I
- Refactor II
- Refactor III (R3)
- Rocketship.vc Fund II
- Rocketship III
- Sci Funder Fellowship
- Shield Capital I
- Sierra Ventures XIII
- Standard Crypto Venture Fund I
- Ubiquity Ventures I
- Ubiquity Ventures II
- Ubiquity III
- Uncork VII
- Uncork Plus III
- Vertex Israel IV
- Vertex Israel V
- Vertex Israel VI
- Vertex Israel VII
- Vertex Opportunity II
- Vertical Venture Partners II
- Vertical Venture Partners III
GENE-EDITING
Enhancing the living environment by counteracting harmful bacteria and germs. Developing new therapies to counteract genetic disorders such as Down Syndrome, Sickle Cell Anemia and Muscular Dystrophy.
ROBOTICS
Micro, Nano and Mini Robotics. A new frontier in surgery and medical diagnosis/ monitoring. Prosthetics that connect to a patient’s central nervous system and ingestible robotics that release precision drugs at regular intervals.
ANTI-AGING
Breakthroughs in understanding what happens when we age and advances in symptom management. Regenerative medicine targeted at slowing the aging process. New discoveries in nutritional intake and improved medical devices.
BRAIN-RELATED
New opportunities in neuroscience such as neurosensing, neurosignaling and neuroplasticity. Improvements in VR, AR, AI and brain-machine interfaces. Future breakthroughs in digital therapeutics for health and mental issues, sleep and natural language processing.